This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Celgene's Abraxane: Two Month Survival Boost In Pancreatic Cancer Trial

SUMMIT, NJ ( TheStreet) -- The addition of Celgene's (CELG - Get Report) cancer drug Abraxane to the chemotherapy drug gemcitabine prolonged the survival of patients with advanced pancreatic cancer by slightly less than two months over treatment with gemcitabine alone, according to results from a phase III study released Tuesday night.

Patients treated with the Abraxane-gemcitabine regimen reported a median overall survival of 8.5 months compared to 6.7 months for patients treated with gemcitabine. That works out to a survival benefit of 55 days, or a day shy of eight weeks.

Celgene announced the detailed Abraxane results in conjunction with the lifting of an embargo on research abstracts to be presented at an American Society of Clinical Oncology meeting focused on gastro-intestinal cancer research that starts Thursday.

The eight-week survival benefit offered by Abraxane is in line with investor expectations, according to a survey conducted last week by ISI Group analyst Mark Schoenebaum.

Celgene shares closed Tuesday down less than 1% to $99.31 ahead of the Abraxane data announcement. In after-hours trading, the stock fell another 1% to $98.25 Celgene has been the highest-flying large-cap biotech stock this year -- up 27% to date -- due to high expectations for accelerating revenue growth (from Abraxane and other drugs) plus optimism about the company's late-stage drug pipeline.

The Celgene contingent value right (CELGZ) tied to Abraxane closed Tuesday up 3% to $7.50, an all-time high.

Abraxane sales could reach $1 billion to $1.25 billion by 2015, Celgene forecast at the J.P. Morgan Healthcare Conference on Jan. 7. Abraxane is approved currently for breast cancer but Celgene plans to seek FDA approval for an expanded label in lung cancer and pancreatic cancer. Final Abraxane sales for 2012 have yet to be released but will likely total around $400 million.

Biotech investors, click here to visit TheStreet's 2013 FDA and EMA drug approval decision calendar.

Abraxane is a novel reformulation of the old chemotherapy drug paclitaxel. In this latest study, 861 treatment-naive pancreatic cancer patients were randomized to treatment with Abraxane plus the chemotherapy gemcitabine or gemcitabine alone. Celgene designed the pancreatic cancer study to show an approximate two-month survival advantage for Abraxane plus gemcitabine over gemcitabine alone. Historically, patients treated with gemcitabine alone live about six months.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CELGZ $1.18 0.85%
CELG $103.41 0.00%
CLVS $13.91 0.00%
THLD $0.44 0.00%
AAPL $93.74 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs